**5. Prognosis**

The data concerning survival are provided in the Annual Report on the Results of Treatment in Gynecological Cancer (Creasman et al. 2006)and are shown in Table 9.


Data taken from Creasman et al, 2006.

Table 9. Carcinoma of the Corpus Uteri: Patients Treated from 1999-2001; Survival Rates by FIGO Surgical Stage.

#### **6. References**

140 Cancer of the Uterine Endometrium – Advances and Controversies

Oncology (NCCN Guidelines™) for Uterine Neoplasms V.2.2011. © 2011 National Comprehensive Cancer Network). A review of symptoms and physical examination is recommended at each visit. The yield of vaginal cytology (0-7%) and CXR (0-20%)for detection of recurrence has been shown to be very low in asymptomatic patients and therefore not currently recommended for routine use(Salani et al. 2011). Although, monitoring CA-125 levels may be beneficial in select patients (advanced stage disease, serous histology, pretreatment elevated CA-125); its routine use is also not supported by the

The data concerning survival are provided in the Annual Report on the Results of Treatment

**Strata Patients 1-Year OS 3-Year OS 5-Year OS** 

**Stage IA 1,054 98.2% 95.3% 90.8%** 

**Stage IB 2,833 98.7% 94.6% 91.1%** 

**Stage IC 1,426 97.5% 89.7% 85.4%** 

**Stage IIA 430 95.2% 89.0% 83.3%** 

**Stage IIB 543 93.5% 80.3% 74.2%** 

**Stage IIIA 612 89.0% 73.3% 66.2%** 

**Stage IIIB 80 73.5% 56.7% 49.9%** 

**Stage IIIC 356 89.9% 66.3% 57.3%** 

**Stage IVA 49 63.4% 34.4% 25.5%** 

**Stage IVB 206 59.5% 29.0% 20.1%** 

Table 9. Carcinoma of the Corpus Uteri: Patients Treated from 1999-2001; Survival Rates by

in Gynecological Cancer (Creasman et al. 2006)and are shown in Table 9.

available evidence (Salani et al. 2011).

Data taken from Creasman et al, 2006.

FIGO Surgical Stage.

**5. Prognosis** 


Campagnutta, E., G. Giorda, G. De Piero, F. Sopracordevole, M. C. Visentin, L. Martella and

Case, A. S., R. P. Rocconi, J. M. Straughn, Jr., M. Conner, L. Novak, W. Wang and W. K. Huh

Chan, J. K., V. Loizzi, M. Youssef, K. Osann, J. Rutgers, S. A. Vasilev and M. L. Berman

COSA-NZ-UK Endometrial Cancer Study Group (1998). Adjuvant medroxy progesterone acetate in high risk endometrial cancer. "Int J Gyn Cancer 8: 387-391. Cragun, J. M., L. J. Havrilesky, B. Calingaert, I. Synan, A. A. Secord, J. T. Soper, D. L. Clarke-

Creasman, W. T., C. P. Morrow, B. N. Bundy, H. D. Homesley, J. E. Graham and P. B. Heller

Creasman, W. T., F. Odicino, P. Maisonneuve, M. A. Quinn, U. Beller, J. L. Benedet, A. P.

Creutzberg, C. L., W. L. van Putten, P. C. Koper, M. L. Lybeert, J. J. Jobsen, C. C. Warlam-

Creutzberg, C. L., W. L. van Putten, P. C. Koper, M. L. Lybeert, J. J. Jobsen, C. C. Warlam-

Creutzberg, C. L., W. L. van Putten, C. C. Warlam-Rodenhuis, A. C. van den Bergh, K. A. de

Therapy in Endometrial Carcinoma Trial." *J Clin Oncol* 22(7): 1234-1241.

Therapy in Endometrial Carcinoma." *Lancet* 355(9213): 1404-1411.

Oncology Group Study." *Cancer* 60(8 Suppl): 2035-2041.

*Gynaecol Obstet* 95 Suppl 1: S105-143.

serous carcinoma of the endometrium." *Gynecol Oncol* 90(1): 181-185. Chi, D. S., M. Welshinger, E. S. Venkatraman and R. R. Barakat (1997). "The role of surgical cytoreduction in Stage IV endometrial carcinoma." *Gynecol Oncol* 67(1): 56-60. Cornelison, T. L., E. L. Trimble and C. L. Kosary (1999). "SEER data, corpus uteri cancer:

study of 12,333 patients." *Cancer* 107(8): 1823-1830.

*Cancer* 100(1): 89-96.

350-355.

3668-3675.

209.

C. Scarabelli (2004). "Surgical treatment of recurrent endometrial carcinoma."

(2006). "A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer." *Obstet Gynecol* 108(6): 1375-1379. Chan, J. K., M. K. Cheung, W. K. Huh, K. Osann, A. Husain, N. N. Teng and D. S. Kapp

(2006). "Therapeutic role of lymph node resection in endometrioid corpus cancer: a

(2003). "Significance of comprehensive surgical staging in noninvasive papillary

treatment trends versus survival for FIGO stage II, 1988-1994." *Gynecol Oncol* 74(3):

Pearson and A. Berchuck (2005). "Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer." *J Clin Oncol* 23(16):

(1987). "Surgical pathologic spread patterns of endometrial cancer. A Gynecologic

Heintz, H. Y. Ngan and S. Pecorelli (2006). "Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer." *Int J* 

Rodenhuis, K. A. De Winter, L. C. Lutgens, A. C. van den Bergh, E. van de Steen-Banasik, H. Beerman and M. van Lent (2000). "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation

Rodenhuis, K. A. De Winter, L. C. Lutgens, A. C. van den Bergh, E. van der Steen-Banasik, H. Beerman and M. van Lent (2003). "Survival after relapse in patients with endometrial cancer: results from a randomized trial." *Gynecol Oncol* 89(2): 201-

Winter, P. C. Koper, M. L. Lybeert, A. Slot, L. C. Lutgens, M. C. Stenfert Kroese, H. Beerman and M. van Lent (2004). "Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation


Homesley, H. D., V. Filiaci, S. K. Gibbons, H. J. Long, D. Cella, N. M. Spirtos, R. T. Morris, K.

Hoskins, P. J., K. D. Swenerton, J. A. Pike, F. Wong, P. Lim, C. Acquino-Parsons and N. Lee

Hricak, H., L. V. Rubinstein, G. M. Gherman and N. Karstaedt (1991). "MR imaging

Humber, C. E., J. F. Tierney, R. P. Symonds, M. Collingwood, J. Kirwan, C. Williams and J.

Kilgore, L. C., E. E. Partridge, R. D. Alvarez, J. M. Austin, H. M. Shingleton, F. Noojin, 3rd

Klopp, A. H., A. Jhingran, L. Ramondetta, K. Lu, D. M. Gershenson and P. J. Eifel (2009).

Kokka, F., E. Brockbank, D. Oram, C. Gallagher and A. Bryant (2010). "Hormonal therapy in

Kuoppala, T., J. Maenpaa, E. Tomas, U. Puistola, T. Salmi, S. Grenman, P. Lehtovirta, M.

Lai, C. H., A. Chao, F. Amant and I. Vergote (2011). "The 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2010)." *Gynecol Oncol* 120(1): 3-4. Lanciano, R. M., W. J. Curran, Jr., K. M. Greven, J. Fanning, P. Stafford, M. E. Randall and G.

radiotherapy." *Gynecol Oncol* 110(2): 190-195.

Group study." *Gynecol Oncol* 112(3): 543-552.

*Radiology* 179(3): 829-832.

751.

56(1): 29-33.

CD007926.

*Oncol* 39(3): 368-373.

DeGeest, R. Lee and A. Montag (2009). "A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology

(2001). "Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study." *J Clin Oncol* 19(20): 4048-4053. Howlader N, N. A., Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary

CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975\_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.

evaluation of endometrial carcinoma: results of an NCI cooperative study."

A. Green (2007). "Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration." *Ann Oncol* 18(3): 409-420. Keys, H. M., J. A. Roberts, V. L. Brunetto, R. J. Zaino, N. M. Spirtos, J. D. Bloss, A. Pearlman,

M. A. Maiman and J. G. Bell (2004). "A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study." *Gynecol Oncol* 92(3): 744-

and W. Conner (1995). "Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling." *Gynecol Oncol*

"Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation." *Gynecol Oncol* 115(1): 6-11.

advanced or recurrent endometrial cancer." *Cochrane Database Syst Rev*(12):

Fors, T. Luukkaala and P. Sipila (2008). "Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-

E. Hanks (1990). "Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium." *Gynecol* 


NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Uterine

Ng, T. Y., J. L. Nicklin, L. C. Perrin, R. Cheuk and A. J. Crandon (2001). "Postoperative

Nout, R. A., H. Putter, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. Lutgens, E. M. van der

results of the randomized PORTEC-2 trial." *J Clin Oncol* 27(21): 3547-3556. Nout, R. A., V. T. Smit, H. Putter, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. Lutgens, E. M.

Olawaiye, A. B. and D. M. Boruta, 2nd (2009). "Management of women with clear cell

Onda, T., H. Yoshikawa, K. Mizutani, M. Mishima, H. Yokota, H. Nagano, Y. Ozaki, A.

Pandya, K. J., B. Y. Yeap, L. M. Weiner, J. E. Krook, J. K. Erban, R. A. Schinella and T. E.

Park, J. Y., E. N. Kim, D. Y. Kim, D. S. Suh, J. H. Kim, Y. M. Kim, Y. T. Kim and J. H. Nam

Pecorelli, S., L. Zigliani and F. Odicino (2009). "Revised FIGO staging for carcinoma of the

Prat, J., A. Gallardo, M. Cuatrecasas and L. Catasus (2007). "Endometrial carcinoma:

Pristauz, G., A. A. Bader, P. Regitnig, J. Haas, R. Winter and K. Tamussino (2009). "How

Randall, M. E., V. L. Filiaci, H. Muss, N. M. Spirtos, R. S. Mannel, J. Fowler, J. T. Thigpen

carcinoma: a Gynecologic Oncology Group Study." *J Clin Oncol* 24(1): 36-44. Rendina, G. M., C. Donadio, M. Fabri, P. Mazzoni and P. Nazzicone (1984). "Tamoxifen and

patients with uterine corpus cancer." *Gynecol Oncol* 108(3): 486-492.

NCCN.org (Accessed 08/01/2011).

trial." *Lancet* 375(9717): 816-823.

therapy." *Br J Cancer* 75(12): 1836-1841.

cervix." *Int J Gynaecol Obstet* 105(2): 107-108.

pathology and genetics." *Pathology* 39(1): 72-87.

endometrial cancer?" *Gynecol Oncol* 115(1): 12-17.

*Gynecol Reprod Biol* 17(4): 285-291.

*Oncol* 113(2): 277-283.

24(1): 43-46.

carcinoma." *Gynecol Oncol* 81(2): 193-195.

Neoplasms V.2.2011. © 2011 National Comprehensive Cancer Network, Inc.

vaginal vault brachytherapy for node-negative Stage II (occult) endometrial

Steen-Banasik, J. W. Mens, A. Slot, M. C. Stenfert Kroese, B. N. van Bunningen, V. T. Smit, H. W. Nijman, P. P. van den Tol and C. L. Creutzberg (2009). "Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first

van der Steen-Banasik, J. W. Mens, A. Slot, M. C. Kroese, B. N. van Bunningen, A. C. Ansink, W. L. van Putten and C. L. Creutzberg (2010). "Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised

endometrial cancer: a Society of Gynecologic Oncology (SGO) review." *Gynecol* 

Murakami, K. Ueda and Y. Taketani (1997). "Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation

Davis (2001). "Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882)." *Am J Clin Oncol*

(2008). "Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of

accurate is frozen section histology of pelvic lymph nodes in patients with

and J. A. Benda (2006). "Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial

medroxyprogesterone therapy for advanced endometrial carcinoma." *Eur J Obstet* 

